𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Protective effect of a low-dose of cyclophosphamide in experimental infection of guinea pigs with junin virus

✍ Scribed by Dr. Carlos Ponzinibbio; Pedro González; Ruben P. Laguens


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
787 KB
Volume
29
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Administration of cyclophosphamide (CY) to guinea pigs infected with a lethal strain of Junin virus (JV) delayed the time of death, with survival of a small number of animals. Virological studies showed a temporary decrease of virus concentration in blood and viscera shortly after the CY injection. In the pathological study no differences were found in the organic lesions present in CY-treated and nontreated animals, with the exception of the pulmonary alterations. In CY-treated guinea pigs the lungs appeared almost normal, but in the control, nontreated animals severe alterations with the pattern of the "respiratory distress syndrome of the adult" were consistently present. In in vitro experiments, incorporation of serum collected from guinea pigs injected 30 minutes before exsanguination with CY to cell cultures, infected with JV, prevented virus replication. On the basis of these results it is suggested that the delay of time of death and eventual survival of CY-treated guinea pigs after JV infection depends on a direct antiviral effect of the drug rather than on its known immunosuppressive action. In addition, the absence of pulmonary alterations in CY-treated animals was tentatively considered to be dependent on the marked polymorphonuclear leukocyte depletion induced by the drug.


📜 SIMILAR VOLUMES


Treatment of chronic hepatitis D virus i
✍ Antonio Madejón; Teresa Cotonat; Javier Bartolomé; Inmaculada Castillo; Dr. Vice 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 633 KB

We examined the efficacy of decreasing high doses (beginning at 18 MU/day) of interferon-%, vs. that of daily low doses (3 MU) in the treatment of chronic hepatitis delta virus infection. Patients treated with 18 MU had a somewhat higher frequency of normalization of serum ALT levels than patients t

Lamivudine therapy in patients undergoin
✍ McCaughan, Geoffrey W. ;Spencer, Jenean ;Koorey, David ;Bowden, Scott ;Bartholom 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 75 KB 👁 1 views

Recurrent hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality after liver transplantation. Recently, antiviral therapy, such as lamivudine, has become available for prophylaxis against HBV reactivation posttransplantation and for the treatment of HBV recurrent disease.